血浆chemerin水平与原发性高血压合并永久性心房纤颤的相关性研究

来源期刊：广州医药 | 13-16 发布时间：2021-11-29 收稿时间：2025/11/13 17:19:50 阅读量：42

作者：: 银孟卓,

卢建文,

关键词：: chemerin 心房颤动高血压; Chemerin Atrial fibrillation Hypertension

DOI：: 10.3969/j.issn.1000-8535.2018.04.004

收稿时间：: 2018-02-27
修订日期：
接收日期：
引用总数：: 0

目的本研究旨在探讨血浆chemerin水平与原发性高血压合并心房颤动的相关性。方法选择2016年2月—2017年12月期间在广州市第一人民医院心内科及老年心内科住院的高血压患者160例,根据是否合并心房纤颤分为心房纤颤组(AF组,n=72)及非心房纤颤组(NAF组,n=88),另选取140例我院体检中心体检结果正常的正常健康人作为对照组(CON组,n=140)。采用全自动生化检测仪测定甘油三脂、总胆固醇、低密度脂蛋白、C反应蛋白等生化学指标;使用ELISA法检测血浆chemerin水平。结果 AF组患者的血浆chemerin水平较NAF组患者升高[(180.45±15.23)ng/mL vs(162.36±13.44)ng/mL,P<0.05],且均较CON组升高[(142.36±11.83)ng/mL,P<0.05)],多元Logistic回归分析显示血浆chemerin水平与高血压病合并心房纤颤呈独立相关性(OR 1.112, 95% CI 1.023～1.302;P<0.001)。结论高血浆chemerin水平可能是预测高血压合并心房纤颤的独立危险因素,血清chemerin可能成为一种预测高血压发生心房纤颤的重要生物学标记物。

1、 ERNST M C, SINAL C J. Chemerin: at the crossroads of inflammation and obesity[J]. Trends Endocrinol Metab, 2010,21(11):660-667.

2、 HARADA M, van WAGONER D R, NATTEL S. Role of inflammation in atrial fibrillation pathophysiology and management[J]. Circ J, 2015,79(3):495-502.

3、 GAMI A S, HODGE D O, HERGES R M,et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation[J]. J Am Coll Cardiol, 2007,49(5):565-571.

4、 THACKER E L, MCKNIGHT B, PSATY B M,et al. Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation[J]. J Gen Intern Med, 2013,28(2):247-253.

5、 BOBBERT T, SCHWARZ F, FISCHER-ROSINSKY A,et al. Chemerin and prediction of diabetes mellitus type 2[J]. Clin Endocrinol (Oxf), 2015,82(6):838-843.

6、 WATTS S W, DORRANCE A M, PENFOLD M E, et al. Chemerin connects fat to arterial contraction[J]. Arterioscler Thromb Vasc Biol, 2013,33(6):1320-1328.

7、 GU P, JIANG W, LU B, et al. Chemerin is associated with inflammatory makers and metabolic syndrome phenotypes in hypertension patients[J]. Clin Exp Hypertens, 2014,36(5): 326-332.

8、 SHIN H Y, LEE D C, CHU S H, et al. Chemerin levels are positively correlated with abdominal visceral fat accumulation[J]. Clin Endocrinol (Oxf), 2012,77(1):47-50.

9、 LANDSBERG L, ARONNE L J, BEILIN L J,et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment——a position paper of the The Obesity Society and The American Society of Hypertension[J]. Obesity (Silver Spring), 2013,21(1):8-24.

10、 FUKUI A, TAKAHASHI N, NAKADA C,et al. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation[J]. Circ Arrhythm Electrophysiol, 2013,6(2):402-409.

11、 SHIN SY,YONG HS,LIM H E,et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation[J]. J Cardiovasc Electrophysiol,2011,22(6):647-655.

12、 WENG C, SHEN Z, LI X, JIANG W,et al. Effects of chemerin/CMKLR1 in obesity-induced hypertension and potential mechanism[J]. Am J Transl Res, 2017,9(6):3096-3104.

13、 BOZAOGLU K, BOLTON K, MCMILLAN J,et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome[J]. Endocrinol, 2007,148(10):4687-4694.